Company news

Immutep Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immutep receives 2nd IND approval for efti from US FDA

March 8, 2020

Immutep reports positive TACTI-002 data

February 18, 2020

Immutep Activities Report

January 28, 2020

Immutep expands Part C of TACTI-002 due to positive data

January 8, 2020

INSIGHT-004 clinical trial update

December 18, 2019

Immutep announces European patent grant for LAG525 antibody

November 13, 2019

Appendix 4C - quarterly

October 23, 2019

Immutep presents positive TACTI-mel melanoma trial data

October 14, 2019

Immutep receives A$2.5M R&D French Tax Incentive

October 9, 2019

Immutep expands Part A of TACTI-002 due to positive data

September 25, 2019

Immutep to receive GBP4M Milestone Payment from GSK

September 22, 2019

Japanese patent granted for LAG525 antibody

September 16, 2019

Immutep granted European patent for IMP321 in cancer

August 21, 2019

Appendix 4E & 2019 Full Year Statutory Accounts

August 20, 2019

Entitlement Offer Results & Shortfall Notification

August 1, 2019

Immutep Entitlement Offer Booklet

July 8, 2019

Immutep completes recruitment of AIPAC trial in MBC

June 24, 2019

Immutep granted Australian patent for eftilagimod alpha

June 20, 2019

Immutep completes recruitment of initial NSCLC cohort

June 13, 2019

First patient dosed in INSIGHT-004

June 5, 2019

Immutep granted European patent for eftilagimod alpha

May 22, 2019

More mature positive data for TACTI-mel trial presented

May 16, 2019

Immutep granted US patent for IMP321

March 21, 2019

IMP761 results presented at ECCO conference

March 7, 2019

Immutep doses First Patient in TACTI-002 Phase II Trial

March 6, 2019

TACTI-mel data presented at World Immunotherapy Congress

March 5, 2019

Half Year Accounts

February 27, 2019

Immutep enters into collaboration with CYTLIMIC

January 6, 2019

Cleansing prospectus for issue of warrants

December 19, 2018

European patent granted for IMP321 & antibody combinations

November 28, 2018

Immutep granted European patent for IMP321

November 27, 2018

Positive interim TACTI-mel data presented at SITC

November 11, 2018

Immutep enters into collaboration with Pfizer & Merck KGaA

September 23, 2018

Progress towards clinical development of IMP761

September 2, 2018

Appendix 4E & 2018 Full Year Statutory Accounts

August 21, 2018

TACTI-mel Patient Recruitment Complete & Operational Update

August 6, 2018

Immutep receives IND approval from US FDA for IMP321

July 31, 2018

Immutep submits IND application with FDA

July 2, 2018

Mid-point of patient enrolment reached in AIPAC trial

June 18, 2018

Webcast slides for TACTI-mel clinical trial data

May 29, 2018

Response to ASX Price Query

May 15, 2018

Immutep raises A$6.85M through institutional placement

March 11, 2018

US patent grant for IMP701 antibody

March 5, 2018

Immutep receives A$686,704 R&D Tax Incentive

March 4, 2018

Outcome of DSMB Safety Review & Extension of TACTI-mel

February 8, 2018

Immutep receives USD1M milestone payment from EOC

February 1, 2018

European patent grant for IMP321 in cancer

November 21, 2017

Japanese Patent Grant for IMP731 Antibody

September 8, 2017

Japanese Patent Grants For IMP321 In Infectious Disease

September 5, 2017

PRR & Monash Uni receive funding grant for LAG-3 Research

August 30, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 112 decks. Every deck is listed under its year.